Table 1 Patient and tumour characteristics
Group | Control | Local recurrence | Brain metastasis | ||
|---|---|---|---|---|---|
primary local | recurrence | primary distant | metastasis | ||
Nr. of patients (pairs) | 43 | 26 (19 pairs) | 25 (19 pairs) | ||
Total number of tumours | 43 | 25 | 20 | 19 | 25 |
Median age (range) | 55 (30–90) | 60 (28–85) | 56 (35–74) | ||
Menopausal category | |||||
Pre-menopausal | 15 | 7 | 9 | ||
Post-menopausal | 27 | 18 | 10 | ||
Unknown/missing | 1 | 0 | 0 | ||
Tumour grade | |||||
Grade 1 | 4 | 1 | 1 | 0 | |
Grade 2 | 29 | 18 | 10 | 8 | |
Grade 3 | 10 | 6 | 3 | 11 | |
Unknown/missing | 0 | 0 | 6 | 0 | |
IHC parameters | |||||
ER status | |||||
Positive | 37 (86%) | 20 (80%) | 17 (85%) | 6 (32%) | 7 (28%) |
Negative | 6 (14%) | 5(20%) | 3 (15%) | 13 (68%) | 18 72%) |
PR status | |||||
Positive | 34 (79%) | 16 (64%) | 12 (60%) | 5 (26%) | 5 (20%) |
Negative | 9 (21%) | 9 (36%) | 8 (40%) | 14 (74%) | 20 (80%) |
Her2 status | |||||
Positive | 4 (9%) | 4 (16%) | 2 (10%) | 11 (58%) | 14 (56%) |
Negative | 37 (86%) | 20 (80%) | 17(85%) | 7 (37%) | 11 (44%) |
Unknown/missing | 2 (5%) | 1 (4%) | 1 (5%) | 1 (5%) | 0 |
MIB-1 | |||||
< 14% | 19 (44%) | 10 (40%) | 6 (30%) | 4 (21%) | 0 |
≥ 14% | 24 (56%) | 14 (56%) | 13 (65%) | 14 (74%) | 25 (100%) |
Unknown/missing | 0 | 1 (4%) | 1 (5%) | 1 (5%) | 0 |
IHC subtype | |||||
lumA | 18 (42%) | 9 (36%) | 6 (30%) | 0 | 0 |
lumB | 17 (40%) | 10 (40%) | 10 (50%) | 6 (32%) | 7 (28%) |
Her2↑ | 1 (2%) | 3 (12%) | 1 (5%) | 8 (42%) | 11 (44%) |
basal | 5 (12%) | 2 (8%) | 2 (10%) | 4 (21%) | 7 (28%) |
Unknown/missing | 2 (5%) | 1 (4%) | 1 (5%) | 1 (5%) | 0 |
PAM50 subtype | |||||
normal | 2 (5%) | 3 (12%) | 0 | 1 (5%) | 0 |
lumA | 17 (40%) | 9 (36%) | 6 (30%) | 3 (16%) | 0 |
lumB | 14 (33%) | 8 (32%) | 9 (45%) | 2 (11%) | 4 (16%) |
Her2↑ | 3 (7%) | 4 (16%) | 3 (15%) | 9 (47%) | 15 (60%) |
basal | 7 (16%) | 1 (4%) | 2 (10%) | 4 (21%) | 6 (24%) |